Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Idiopathic (Essential) Hypertension - Pipeline Review, H2 2014', provides an overview of the Idiopathic (Essential) Hypertension's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Idiopathic (Essential) Hypertension Overview 7
Therapeutics Development 8
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 8
Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis 9
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 10
Idiopathic (Essential) Hypertension - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic (Essential) Hypertension - Products under Development by Companies 15
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 16
Eli Lilly and Company 16
Daiichi Sankyo Company, Limited 17
Merck & Co., Inc. 18
Novartis AG 19
Actelion Ltd 20
Forest Laboratories, Inc. 21
Les Laboratoires Servier SAS 22
Bayer AG 23
Ahn-Gook Pharmaceutical Co., Ltd. 24
PhaseBio Pharmaceuticals, Inc. 25
Lee's Pharmaceutical Holdings Limited 26
Idiopathic (Essential) Hypertension - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 32
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
(nebivolol + valsartan) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(perindopril + amlodipine besilate) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
(sacubitril + valsartan) - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
carvedilol - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
(nifedipine + candesartan cilexetil) - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
(losartan potassium + hydrochlorothiazide + amlodipine besylate) - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
CS-3150 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
rostafuroxin - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
ACT-280778 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
LY-2623091 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
PB-1046 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
PB-1120 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Idiopathic (Essential) Hypertension - Recent Pipeline Updates 55
Idiopathic (Essential) Hypertension - Dormant Projects 60
Idiopathic (Essential) Hypertension - Product Development Milestones 61
Featured News & Press Releases 61
Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 61
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2014 8
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H2 2014 9
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 12
Comparative Analysis by Clinical Stage Development, H2 2014 13
Comparative Analysis by Early Stage Development, H2 2014 14
Products under Development by Companies, H2 2014 15
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2014 16
Idiopathic (Essential) Hypertension - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 17
Idiopathic (Essential) Hypertension - Pipeline by Merck & Co., Inc., H2 2014 18
Idiopathic (Essential) Hypertension - Pipeline by Novartis AG, H2 2014 19
Idiopathic (Essential) Hypertension - Pipeline by Actelion Ltd, H2 2014 20
Idiopathic (Essential) Hypertension - Pipeline by Forest Laboratories, Inc., H2 2014 21
Idiopathic (Essential) Hypertension - Pipeline by Les Laboratoires Servier SAS, H2 2014 22
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2014 23
Idiopathic (Essential) Hypertension - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 24
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2014 25
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2014 26
Assessment by Monotherapy Products, H2 2014 27
Assessment by Combination Products, H2 2014 28
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 34
Number of Products by Stage and Route of Administration, H2 2014 36
Number of Products by Stage and Molecule Type, H2 2014 38
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H2 2014 55
Idiopathic (Essential) Hypertension - Dormant Projects, H2 2014 60